SBIR/STTR Research Award

Molecular Breeding of Gene Therapy Vectors

Award identifier c764f1a1f0c1246676c9cfd98cfccc7c0497fc7e0b15c271748f33c5828ed2acAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$131,711

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
APPLIED GENETIC TECHNOLOGIES CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): We propose to develop Gene Therapy vectors that are targeted to particular cell membrane receptors, cell types and/or tissues. Development of these precise delivery systems will help overcome potential adverse reactions and high dosing requirements imposed by the current, non-targeted, traditional Gene Therapy vectors. The goal in Phase I is to construct a combinatorial library of chimeric Adeno-associated virus (AAV) vectors to screen for tissue-specific targeting during Phase II. Because of technical limitations, AAV-based combinatorial libraries were not previously available. We plan to use a unique new technology for building and subsequent selection of AAV vector libraries. Specifically, we will exploit molecular breeding of viruses by DNA shuffling to direct evolution in vitro of AAV capsid genes through recombination of multiple homologous parental sequences of known AAV serotypes. To construct the library, we will use a new AAV production technology based on insect cells and genome pseudotyping. Researchers at AGTC and UF Powell Gene Therapy Center, with proven track records in the AAV field, will join efforts to complete the project. During the feasibility study, we will demonstrate whether it is possible to build an AAV-based library of viable viral clones of at least 106 complexity using recombination of capsid genes of AAV1 and AAV2 serotypes. The successful completion of this step will allow us to proceed to the next stage of selection of vectors with a particular cell/tissue tropism completed during Phase II of the project. We anticipate to market AAV combinatorial libraries to users within the gene therapy community, as a product to select for delivery vectors targeted to a particular tissue or tailored to a particular application, e.g. targeted delivery of pro- apoptotic or suicidal genes to tumors. This project will represent a significant advance in the development of therapeutic gene delivery systems with precise targeting to improve patient outcomes.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.